Defense Secretary Pete Hegseth announced that active-duty service members 30 and older will be screened annually for testosterone deficiency as part of the periodic health assessment they already complete, with troops under 30 able to request the test voluntarily. Treatment, if recommended, remains the individual's choice.

Hegseth framed it as a readiness measure, saying the initiative is not about artificial enhancement but about restoring and optimizing your natural capabilities, protecting your longevity, and ensuring you have the biological foundation required to sustain the fight.

The policy question underneath is not really about testosterone. It is about screening, which is a distinct medical discipline with its own evidence standards, and the distinction explains most of the clinical objections.

Why screening is a different question from treating

Diagnostic testing means testing someone who has symptoms, to find out why. Screening means testing people without symptoms, to find disease before it announces itself.

Those require different evidence. A test can be excellent at confirming a diagnosis in a symptomatic patient and still be a poor screening tool, because screening asymptomatic populations only helps if finding the condition early leads to treatment that improves outcomes, and if the benefits exceed the harms of overdiagnosis.

Here is where the guidelines sit. The American Urological Association and the Endocrine Society advise testosterone supplementation only for patients with confirmed testosterone deficiency and symptoms such as reduced libido, erectile dysfunction, fatigue, decreased muscle mass, and low bone density.

Confirmed deficiency and symptoms. A screening program by construction identifies people who have the first without the second, and that group is precisely the one the guidelines do not address.

The evidence gap was put plainly by Dr. Kevin McVary: patients report that treating low testosterone improves cognitive alertness and stamina, but the evidence is not concrete, and it comes from patients who were treated because they were symptomatic. Extrapolating from symptomatic patients who improved to asymptomatic people who might is exactly the inference screening programs are supposed to test rather than assume. Worth noting for transparency: McVary sits on the medical advisory board of a telehealth platform that provides testosterone supplements, so the caution is coming from someone with commercial exposure to the opposite conclusion.

Four of six doctors interviewed by Reuters said there was no solid evidence that screening all military personnel aged 30 and older would optimize U.S. readiness for combat.

The occupational problem nobody is discussing

Here is the clinical complication specific to this population, and it may be the most important thing about the program.

Testosterone is not a stable trait. It varies substantially with time of day, peaking in the morning, and drops with acute illness, sleep deprivation, caloric deficit, intense physical exertion, and psychological stress. Research indicates a strong connection between stress and low testosterone levels, including in younger men.

Now consider the population being screened. Military service involves chronic sleep disruption, sustained physical demand, caloric and recovery deficits during operations and training, and elevated stress. Those are not incidental features; they are the job.

So a screening program applied to this population should be expected to find a substantial number of low readings that reflect operational conditions rather than an underlying endocrine disorder. The physiologically correct response to that finding is rest, recovery, nutrition, and load management. The pharmacological response is hormone replacement.

If low readings driven by operational tempo get treated as deficiency requiring supplementation, the program would medicate a symptom of overwork rather than address it. That is a real risk, and it is a design question the Pentagon has not addressed publicly. A protocol requiring morning draws, repeat confirmation on a separate day, and a workup for reversible causes before any treatment discussion would largely solve it. Whether such a protocol exists is unknown.

The strongest argument in favor

The case for screening is not empty, and it rests on the reversible-causes point.

Dr. Mohammed of Gameday Health noted that testosterone is one of the most useful blood tests available to gauge health in men, and that broader screening would identify many men with reversible causes and some with true deficiency, with both groups benefiting from clinician-guided care, whether that means correcting reversible causes or starting treatment when warranted. He specifically noted that reservists may be overweight, another correctable contributor.

That argument is sound, with one condition attached: it holds only if a low result triggers an investigation rather than a prescription. Low testosterone is associated with obesity, poor sleep, metabolic syndrome, thyroid disorders, opioid use, and depression. A screening program that routes abnormal results into a workup could genuinely improve health by surfacing those conditions. A program that routes them toward replacement therapy would treat the marker and leave the cause.

There is also a legitimate clinical reason to care. Testosterone deficiency, which affects roughly 5.6% of men between 30 and 79, is linked to diabetes, cardiovascular disease, osteoporosis, and depression. Identifying it in a young, otherwise healthy population has plausible long-term value independent of any combat-readiness claim.

What treatment actually commits someone to

Two features of testosterone replacement therapy deserve more attention than the announcement gave them, because they matter specifically to a military-age workforce.

Exogenous testosterone suppresses the body's own production through negative feedback, which means TRT is typically a long-term or lifelong commitment. Stopping often leaves a person worse off temporarily than before starting, while natural production recovers, if it does.

More significantly for this population, TRT suppresses sperm production and can impair fertility, sometimes durably. For a workforce concentrated in prime reproductive years, that is a material consideration, and it argues for fertility counseling as a standard part of any treatment discussion rather than an afterthought.

Framing the decision as entirely your choice is appropriate and important. Informed choice requires that these specific trade-offs be part of the conversation, in an institutional culture where declining an offered performance intervention may not feel entirely neutral.

The unanswered operational questions

Several practical gaps remain, and they are the ones service members should want resolved.

The department has not said when screening will start, how much the added testing will cost, or how it will be phased in across the services. More consequentially, it has not detailed how a deficiency result will be recorded, who will have access to it, or whether it could have any effect on a member's assignments or career.

That last set matters most. A result recorded in a service member's medical file, with unclear access rules and unclear career implications, changes the incentive structure around the whole program. If troops suspect a low reading could affect assignments, some will avoid the encounter or the follow-up, which undermines both the readiness rationale and the health rationale.

The Pentagon also declined to say whether female service members would receive hormone screening, and Hegseth's announcement did not specify whether testing and treatment would be gender-specific. Since women also produce testosterone and hormonal health affects readiness in both sexes, and since one researcher noted broad screening could reveal new information about female soldiers' hormones, the omission is a substantive gap rather than a rhetorical one.

The reasonable version

Congress has been circling this for a while. A provision in the fiscal 2025 defense bill asked the Secretary of Defense to brief members on the military's available treatments for low testosterone and current protocols for testing and screening, so the underlying interest predates this announcement and is bipartisan in origin.

There is a version of this program that is straightforwardly good medicine: morning-draw testing with confirmatory repeat, results routed into a workup for sleep, weight, metabolic, and mental health causes, treatment reserved for confirmed deficiency with symptoms per existing guidelines, fertility counseling built into the treatment discussion, and clear firewalls between medical results and career decisions. There is also a version that is a lot of tests generating a lot of borderline results in a population whose job depresses the measurement, with prescriptions as the path of least resistance. The distinction lies entirely in the clinical protocol, which has not been published.

Further reading